Company intelligence / Profile preview
Ochre Bio
Oxford, England, UKochre-bio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing RNA therapies using human organ models to address chronic liver diseases and improve transplant outcomes. Recent $37.5M GSK partnership focuses on AI-driven target discovery[6][7].
- Therapeutic areas
- Gastroenterology
- Modalities
- RNA therapiessiRNAs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ochre Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ochre Bio.